Search Results
Oct 19, 2025, 21:00 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
tumors, today announced that the latest results from the ongoing Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]), were presented in a Poster Presentation at the European Society for Medical Oncology Congress 2025 (ESMO 2025) in Berlin, Germany.
More news about: Antengene Corporation Limited
Oct 19, 2025, 20:10 ET ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
Phase I data for CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody) and the Phase Ib study design for CS5001 (a ROR1-targeted Antibody-Drug Conjugate [ADC]) at the 2025 European Society for Medical Oncology (ESMO) Annual Congress. Key Highlights of CS2009 Poster
More news about: CStone Pharmaceuticals
Oct 19, 2025, 08:45 ET SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO
Iza-bren is a potentially first-in-class topoisomerase 1 inhibitor-based bispecific antibody-drug conjugate (ADC) which targets both epidermal growth factor receptor and human epidermal growth factor receptor 3 (EGFRxHER3). It is being developed by Biokin in China
More news about: SystImmune, Inc.
Oct 19, 2025, 03:00 ET Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
biopharmaceutical company focused on the development of ADC drugs, today announced interim results from its ongoing Phase I/II open-label, multicenter dose escalation and expansion study evaluating AMT-253, a MUC18-directed antibody-drug-conjugate (ADC), in patients with melanoma and other advanced solid
More news about: Multitude Therapeutics, Inc.
Oct 19, 2025, 03:00 ET 普眾發現在2025年歐洲腫瘤內科學會（ESMO）上公布其抗MUC18 ADC（AMT-253）用於晚期惡性黑色素瘤及其他實體瘤的初步積極數據
AMT-253 展現出良好可控的安全性，與其他 TOP1 抑制劑類 ADC 一致 在未經MUC18表達篩選、經多線治療的惡性黑色素瘤和婦科腫瘤受試者中觀察到積極療效信號
More news about: 普眾發現
Oct 18, 2025, 10:42 ET Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
projects are in the clinical stage. The company has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC project approved for marketing and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 18, 2025, 10:30 ET PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
PADCEV™ (enfortumab vedotin) PADCEV™ (enfortumab vedotin) is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.5 Nonclinical data suggest
More news about: Astellas Pharma Inc.
Oct 18, 2025, 03:00 ET Florida Cancer Specialists & Research Institute Shaping the Future of Cancer Care at Global Congress
antibody–drug conjugate (ADC), in patients with metastatic or unresectable NSCLC and other solid tumours. Judy S. Wang, MD:First- in- Human Study of the First-in-class Non-cellular Targeting Antibody-Drug Conjugate (ADC), MICVO, in Patients with
More news about: Florida Cancer Specialists & Research Institute
Oct 17, 2025, 10:37 ET Wobble Genomics Presents Latest Data at ESMO: establishing the robustness of an enhanced liquid biopsy platform for sensitive detection of low-abundance RNA
spectrum. The method identified novel isoforms of key cancer genes HER2 and TROP2 in patient blood samples, allowing more effective ADC development and more accurate patient stratification. Dr. Richard Kuo, Wobble Genomics CEO and Founder, said: "Our new platforms
More news about: Wobble Genomics
Oct 17, 2025, 10:00 ET Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
clinical-stage company focused on the development of antibody-drug-conjugate (ADC) drugs, today announced initial data from its ongoing phase I/II open-label, multicenter dose escalation and expansion study evaluating AMT-116, a CD44v9-directed ADC, in patients with EGFR wild-type NSCLC and other advanced solid tumors.
More news about: Multitude Therapeutics, Inc.
Oct 17, 2025, 10:00 ET 普眾發現在2025年歐洲腫瘤內科學會（ESMO）上公佈其抗CD44v9 ADC（AMT-116）用於晚期EGFR野生型非小細胞肺癌（NSCLC）及其他晚期實體瘤的初步積極數據
標題：Updated ongoing Phase I/II clinical trial results of AMT-116, a first-in-class anti-CD44v9 antibody-drug conjugate (ADC), in patients with advanced solid tumors 口頭匯報專題： Developmental therapeutics
More news about: 普眾發現
Oct 17, 2025, 10:00 ET SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
global phase I US-Lung-101 study (NCT05983432) of iza-bren (BL-B01D1), a potentially first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. Iza-bren is jointly developed by SystImmune and Bristol Myers
More news about: SystImmune, Inc.
Oct 17, 2025, 08:00 ET Marengo Presents Initial Phase 2 Results Demonstrating Broad Single-Agent Activity of Invikafusp Alfa Across Multiple PD-1-Refractory or -Resistant Solid Tumors as a Late-Breaking Oral Presentation at ESMO 2025
biomarker TMB-H in large indications, the company is also progressing a Phase 2 combination with Trodelvy® (TROP2-directed ADC) in TNBC and HR+/HER2– breast cancer to evaluate synergy in ADC and IO settings. Invikafusp alfa is a first-in-class, bispecific dual T-cell agonist designed
More news about: Marengo Therapeutics
Oct 17, 2025, 05:42 ET Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
projects are in the clinical stage. The company has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 16, 2025, 23:13 ET Wang Qunbin: Innovation-Driven, Fosun's Path to Globalization
HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, Japan, and Australia. Currently, no PD-L1 ADC has been approved globally, positioning HLX43 as
More news about: Fosun
Oct 16, 2025, 11:04 ET Tagworks Pharmaceuticals anuncia el inicio del ensayo clínico de fase 0/1 para TGW211
tecnología patentada Click-to-Release en diversas modalidades terapéuticas, incluyendo conjugados anticuerpo-fármaco (ADC) y radiofármacos dirigidos. Sus programas principales incluyen TGW101, un ADC dirigido a TAG-72, un marcador no internalizante presente en la superficie de muchas células tumorales sólidas,
More news about: Tagworks Pharmaceuticals BV
Oct 16, 2025, 10:41 ET Tagworks Pharmaceuticals gibt die Genehmigung durch die CTA und den Beginn der klinischen Phase-0/1-Studie für TGW211 bekannt, ein Radiopharmazeutikum zur Behandlung von HER2+-Tumoren
einsetzt, darunter Antikörper-Wirkstoff-Konjugate (ADCs) und gezielte radiopharmazeutische Therapien. Zu den führenden Programmen gehören TGW101, ein ADC, der auf TAG-72 abzielt, einen nicht-internalisierenden Marker, der auf der Oberfläche vieler solider Tumorzellen zu finden ist, sowie TGW211, ein Radioimmunokonjugat,
More news about: Tagworks Pharmaceuticals BV
Oct 16, 2025, 10:39 ET Tagworks Pharmaceuticals annonce l'autorisation du CTA et le début de l'essai clinique de phase 0/1 pour TGW211, un produit radiopharmaceutique pour le traitement des tumeurs HER2+
Click-to-Release dans une gamme de modalités thérapeutiques, y compris les conjugués anticorps-médicaments (ADC) et les thérapies radiopharmaceutiques ciblées. Ses principaux programmes comprennent TGW101, un ADC ciblant TAG-72, un marqueur non internalisant présent à la surface de nombreuses cellules tumorales
More news about: Tagworks Pharmaceuticals BV
Oct 15, 2025, 09:11 ET Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Sabeen Mekan, M.D., Senior Vice President of Clinical Development of Zymeworks. "These initial results reinforce our confidence in our novel ADC design and its potential to deliver improved treatments for broader patient populations." The company will host a live webcast
More news about: USA News Group
Oct 15, 2025, 07:00 ET Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors
therapeutics modalities, including antibody-drug conjugates (ADCs) and targeted radiopharmaceutical therapies. Its lead programs include, TGW101, an ADC targeting TAG-72, a non-internalizing marker found on the surface of many solid tumor cells and TGW211, a radioimmunoconjugate targeting HER2-positive
More news about: Tagworks Pharmaceuticals BV
Oct 15, 2025, 07:00 ET Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors
therapeutics modalities, including antibody-drug conjugates (ADCs) and targeted radiopharmaceutical therapies. Its lead programs include, TGW101, an ADC targeting TAG-72, a non-internalizing marker found on the surface of many solid tumor cells and TGW211, a radioimmunoconjugate targeting HER2-positive
More news about: Tagworks Pharmaceuticals BV
Oct 15, 2025, 02:00 ET La vidéo "Diabète & Préjugés » développée par Abbott révèle que les idées reçues peuvent avoir un impact sur la prise en charge des personnes vivant avec un diabète.
de presse.Abbott France SAS 40-48 rue d'Arcueil, 94593 Rungis cedex, France, CP 10157 602 950 206 RCS Créteil©2025 Abbott. INSTIT-ADC-121435V1 10/25
More news about: Abbott
Oct 14, 2025, 12:00 ET Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress
(688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical research results of its novel B7-H3-targeting ADC (R&D code: 7MW3711) for multiple advanced solid tumors, will be presented as a poster at the European Society for Medical Oncology (ESMO) Congress
More news about: Mabwell
Oct 14, 2025, 08:00 ET Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA
self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the National Medical Products Administration (NMPA) in China to initiate clinical study in patients with advanced solid tumors. 7MW4911 is an investigational CDH17-targeting ADC developed using Mabwell's
More news about: Mabwell
Oct 14, 2025, 03:30 ET Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points
programs. His leadership in bringing ENHERTU, a pioneering ADC for breast cancer, from initial first-in-human clinical studies to global approval, exemplifies his deep expertise and will be invaluable to Ona as it advances its innovative ADC pipeline toward clinical development.
More news about: Ona Therapeutics